Traditionally, the tumour-promoting effect of UCP2 has been ascribed to a reduction in ROS levels in cancer cells, achieved by lowering the electrochemical gradient across the inner mitochondrial membrane due to its protonophoric activity. The gene discussed is UCP2; the disease is neoplasm.